FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Börse Stuttgart 12:14:16 14/06/2024 BST | ||
| 482.8 EUR | -3.57% |
|
| Current month | +27.25% | ||
| 1 month | +28.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 482.8 | -3.57% |
| 13/06/24 | 500.6 | +1.00% |
| 12/06/24 | 495.7 | +1.06% |
| 11/06/24 | 490.5 | -1.59% |
| 10/06/24 | 498.4 | +4.61% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 12:14 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA7CBB |
| ISIN | DE000MA7CBB0 |
| Date issued | 10/06/2021 |
| Strike | 793.2 kr |
| Maturity | Unlimited |
| Parity | 0.05 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 500.6 € |
|---|---|
| Lowest since issue | 10.25 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
